ArticleBMC cancer2024

Transarterial chemoembolization with molecular targeted therapies plus camrelizumab for recurrent hepatocellular carcinoma.

Changlong Hou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.